• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

CORRECTING and REPLACING Vim, a Healthcare Platform for Health Plan-provider Collaboration, Raises $24 Million in Series B Financing Led by Optum Ventures and Premera Blue Cross

Share:

September 17, 2019

Please replace the release with the following corrected version due to multiple revisions.

The corrected release reads:

VIM, A HEALTHCARE PLATFORM FOR HEALTH PLAN-PROVIDER COLLABORATION, RAISES $24 MILLION IN SERIES B FINANCING LED BY OPTUM VENTURES AND PREMERA BLUE CROSS

Vim, Inc., a health care technology company that aligns incentives between health plans and care providers to empower value-based care decisions, has completed a $24 million Series B financing round led by Optum Ventures and Premera Blue Cross. The round also included follow-on investments by Great Point Ventures and Sequoia Capital and an investment from Leverage Health Solutions.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Vim will use this investment to fuel rapid expansion across new U.S. markets, and accelerate product development and hiring initiatives.

Health plans and care providers still face significant challenges working together to drive value-based care. Vim’s platform helps promote affordable, convenient, high-quality care by helping doctors choose the right care providers and guiding patients to optimal care providers through online booking. The company’s platform is powered by collective intelligence from health care data and human expertise.

“Vim’s platform helps remove the complexity of navigating the health care system and uniquely positions us to align stakeholders. It’s more important than ever that we use technology to help patients access high-quality care and reward care providers for delivering value. We’ve already proven we can drive a meaningful impact in Washington, Alaska, Florida and Texas, and we’re excited to leverage our recent investment to reach more patients and care providers,” said Vim’s co-founder and CEO Oron Afek.

“Vim’s unique ability to help patients find, schedule and receive the highest-quality care while promoting health plan and care provider collaboration will lead to better care outcomes for patients,” said Jon Bunker, Fund Advisor for Optum Ventures.

Richard Lungen, managing member of Leverage Health Solutions and pioneer in structuring Vim’s go to market strategy commented, “Vim is achieving incredible results with its clients, proving that they are well-positioned to continue to drive real value and define the marketplace. These investments are a material validation of Vim’s value proposition and growth.”

Date: September 17, 2019

Source: Finance Yahoo

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Is Remote-Learning A Public Health Dilemma?Is Remote-Learning A Public Health Dilemma?
  • Northwell Selects Cedar to Deliver Personalized Financial ExperienceNorthwell Selects Cedar to Deliver Personalized Financial Experience
  • Private Group RLS (USA) Inc. Acquires GE Healthcare’s U.S. Radiopharmacy NetworkPrivate Group RLS (USA) Inc. Acquires GE Healthcare’s U.S. Radiopharmacy Network
  • Wedgewood Pharmacy Completes Acquisition of Wildlife Pharmaceuticals and Its Subsidiary ZooPharm; Appoints New Wildlife General ManagerWedgewood Pharmacy Completes Acquisition of Wildlife Pharmaceuticals and Its Subsidiary ZooPharm; Appoints New Wildlife General Manager
  • Meet the Scientists Bringing Extinct Species Back From the DeadMeet the Scientists Bringing Extinct Species Back From the Dead
  • 5 Ways Artificial Intelligence is Transforming Digital Pathology5 Ways Artificial Intelligence is Transforming Digital Pathology
  • Hardy Diagnostics awarded Manual Microbiology agreement with Premier, Inc.Hardy Diagnostics awarded Manual Microbiology agreement with Premier, Inc.
  • Novo follows Sanofi, Lilly with insulin price cut in USNovo follows Sanofi, Lilly with insulin price cut in US

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications